Effect of Weight Loss on Cardiovascular Disease Risk Factors in Obese Women

Completed · Not applicable

Conditions studied: Obesity, Cardiovascular Diseases

In brief

The purpose of this study is to examine the effect of weight loss and exercise on cardiovascular disease risk factors, specifically inflammation as measured by C-Reactive Protein and cardiac structure and function as measured by cardiac MRI, in Class II and III obese women during a 12 week training intervention.

Key facts

Study ID

NCT01353001

Run by

University of Pittsburgh

People needed

24

Starts

2011-04-01

Expected to finish

2011-07-01

Last updated by the study team

2016-01-05

Who can join

Age: 30 and older, up to 55. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female
• 30-55 years of age
• BMI = 35.0-44.9 kg/m2

You may not qualify if…

• Currently pregnant, pregnant in the past 6 months, or planning on becoming pregnant in the next 6 months.
• Regularly exercising for greater than 60 minutes per week.
• Taking prescription or over-the-counter medications that affect body weight, metabolism, blood pressure, or heart rate, such as psychotropic medications (e.g. zoloft, prozac, paxil, xanax) and medications that have metabolic effects (e.g. synthroid, wellbutrin, metformin).
• Having physical limitations that hinder or prevent exercise.
• Currently being treated for coronary heart disease, diabetes mellitus, hypertension, or cancer.
• Having a resting systolic blood pressure of > 150mmHg of diastolic blood pressure of > 100mmHg or currently taking any medications that affect blood pressure or heart rate (i.e. beta blockers).
• Currently enrolled in an exercise or weight control study or participating in an exercise or weight control study in the past 6 months.
• Have lost and not regained > 5% body weight in the past 6 months.
• Currently being treated for any psychological problems or taking any psychotropic medications.
• Abnormal kidney functions, as per current institutional standard for gadolinium administration.
• Known allergy to IV gadolinium, or the discovery of an allergic reaction to IV gadolinium at baseline.

Where it is running

• Physical Activity and Weight Management Research Center, Suite 600 Birmingham Towers — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.